Funding for novel lysosomal protease inhibitors for the treatment of Alzheimer’s disease
January 24, 2024Alzheimer’s disease is becoming a healthcare burden of epidemic proportions for which there is no cure. UvA researcher Dr. Ewelina Weglarz-Tomczak addresses the underlying molecular mechanisms of neurodegeneration in the disease. She will be bringing her invention one step closer to clinic with a €100,000 proof-of-concept grant by IXA to evaluate the designed lead structures in cell-based models.
It is estimated that there are approximately 44 million people worldwide living with Alzheimer’s disease (AD) or a related form of dementia. AD has no cure, there are two recently approved antibody treatments that demonstrate removing β-amyloid (βA), one of the hallmarks of AD. Still, they are highly controversial due to their severe side effects such as brain swelling or bleeding (up to 40% of patients).
New treatment with novel lysosomal protease inhibitors
Dr. Ewelina Weglarz-Tomczak’s approach addresses the underlying biology of the disease by targeting two highly specified lysosomal protease (proteolytic enzyme located in lysosomes which
breaks down targeted proteins) which are the key factors in the molecular mechanisms of neurodegeneration in AD. AI-powered technology developed by NatInLab (spin-off company of Dr. Ewelina Weglarz-Tomczak’s) has led to the discovery of how that protease is controlled in the human organism. Based on this knowledge, developing novel, highly effective and safe inhibitors of targeted protease is possible.
Proof-of-concept grant
IXA has provided Dr. Ewelina Weglarz-Tomczak support in bringing her invention one step closer to clinic with a €100,000 proof-of-concept grant to evaluate the designed lead structures in cell-based models. The project aims to deliver new agents against Alzheimer’s and possibly other neurodegenerative diseases as the next step.
More information
More news
Tackling learning difficulties in Academic Workplace
The Academic Workplace Rudolf Berlin Center (AW RBC) aims to make a meaningful contribution by supporting young people with learning disabilities through enhanced education and care.
News
VU researchers develop research equipment to identify contaminants in water
Water, comprising over 70% of our planet, is the source of all life. The presence of emerging contaminants in our water, including pharmaceuticals, pose serious health and environmental risks, such as DNA damage, reproductive issues, and cancer. New equipment to detect these contaminants developed by VU researchers has been sold to other research groups all over the world. Now the researchers are taking the next step, together with IXA, to expand sales to water companies worldwide as well as other applications such as food and drug discovery research.
News
Contribute to Amsterdam’s Future: test your innovation at SAIL and the Amsterdam Marathon
Are you looking for a testing ground for your innovation? SAIL and the Amsterdam Marathon present an excellent opportunity to test your ideas. These major events attract millions of visitors and come with sustainability, accessibility, and logistical challenges that need fresh solutions. The In Residence Events program allows you to test your innovation during these […]
News